Overexpression of miR-146a and miR-155 are Potentially Biomarkers and Predict Unfavorable Relationship between Gastric Cancer and Helicobacter pylori Infection / 전남의대학술지

Gastric Cancer (GC) is one of the most dangerous malignancies in the world. This study aims to evaluate the relationship between miR-146a and miR-155 in patients with H. pylori infections with GC compared to H. pylori-infected patients and healthy subjects. Forty patients with H. pylori and GC positive diagnoses and 40 patients with H. pylori positive and GC negative diagnoses, and 40 healthy persons were selected.The expression of miR-146a and miR-155 genes in the whole blood was examined using qRT-PCR. Moreover, ROC curves were drawn to represent the sensitivity and specificity of miR-146a and miR-155 expression as biomarkers. The results showed the expression of miR-146a and miR-155 in the whole blood of patients with H. pylori and GC positive diagnoses are significantly higher than in healthy individuals and are non-significantly enhanced compared to H. pylori positive and GC negative. Also, the results stated miR-146a and miR-155 expression in the whole blood of patients who are H. pylori positive and GC negative are significantly increased compared to healthy individuals. Furthermore, the ROC curve analysis of miR-146a and miR-155 RNA level demonstrated the two miRNAs have an appropriate sensitivity and specificity for diagnostic goals. In conclusion, H. pylori infection may increase the expression of miR-146a and miR-155 in patients with H. pylori and GC positive diagnoses, which can be effective in the curbing the progression of GC. For this reason, up-regulation of miR-146a and miR-155 along with H. pylori infection might contribute to the pathogenesis of GC, and also can be suggested as biomarkers for GC diagnosis and treatment.

Macrophage migration inhibitory factor antagonist (p425) ameliorates kidney histopathological and functional changes in diabetic rats / Antagonista (p425) do fator de inibição da migração de macrófagos (MIF) melhora as alterações histopatológicas e funcionais renais em ratos diabéticos

Abstract Introduction: It is hypothesized that increased macrophage migration inhibitory factor (MIF) expression may contribute to diabetic nephropathy (DN) pathogenesis. The aim of the present study was to investigate the renal effects of MIF inhibition in a diabetic experimental model. Methods: Eighteen male Wistar rats (230 ± 20 g) were divided into three groups: 1) control, 2) diabetic (STZ, 50 mg/kg, dissolved in saline, ip), 3) diabetic + MIF antagonist (p425, 1 mg/kg per day, ip, on the 21th day, for 21 consecutive days). The treatment started since we founwd a significant increase in urine albumin excretion (UAE) rate in the diabetic rats in comparison with the control rats. The rats were kept individually in metabolic cages (8 AM-2 PM) and urine samples were collected in the 21 and 42th day. At the end, blood and tissue samples were collected for biochemical (BS, UPE, urine GAG, BUN, Cr, Na, and K) and histological analyses. Results: The results of this study showed that MIF antagonist (p425) significantly decreased urine protein and GAG excretion, urine protein/creatinine ratio, and serum BUN and Cr in the streptozotocin-induced DN in the rats. Pathological changes were significantly alleviated in the MIF antagonist (p425)-administered DN rats. Conclusion: Collectively, these data suggested that MIF antagonist (p425) was able to protect against functional and histopathological injury in the DN.

Resumo Introdução: Supõe-se que elevações da expressão do fator de inibição da migração de macrófagos (MIF) possam contribuir para a patogênese da nefropatia diabética (ND). O objetivo do presente estudo foi investigar os efeitos renais da inibição do MIF em um modelo experimental diabético. Métodos: Dezoito ratos Wistar machos (230 ± 20g) foram divididos em três grupos: 1) controle, 2) diabético (STZ 50 mg/kg dissolvida em soro fisiológico, IP), 3) diabético + antagonista do MIF (p425 1 mg/kg por dia IP no 21o dia por 21 dias consecutivos). O tratamento começou após a identificação de aumento significativo na albuminúria nos ratos diabéticos em relação aos controles. Os ratos foram mantidos individualmente em gaiolas metabólicas (8h-14h) e amostras de urina foram colhidas no 21o e no 42o dia. Ao final do estudo, amostras de sangue e tecido foram colhidas para análises bioquímicas (BS, excreção urinária de proteína, excreção urinária de GAGs, BUN, Cr, Na e K) e histológicas. Resultados: O presente estudo demonstrou que o antagonista do MIF (p425) diminuiu significativamente proteinúria, excreção urinária de GAGs , relação proteína/creatinina na urina, BUN e Cr no grupo com ND induzida por estreptozotocina. As alterações patológicas foram significativamente abrandadas nos ratos com ND que receberam antagonista do MIF (p425). Conclusão: Coletivamente, os dados sugerem que o antagonista do MIF (p425) teve efeito protetor contra lesões funcionais e histopatológicas da ND.

comparison of spot urine protein-creatinine ratio with 24-hour urine protein excretion in women with preeclampsia

Proteinuria is an important diagnostic component of preeclampsia. We prospectively compared the results of spot urine protein-creatinine [P/C] ratio with 24-hour urine protein excretion in women with preeclampsia. A total of 81 pregnant women with preeclampsia were prospectively studied for proteinuria. Urine P/C ratio was determined in a spot mid-stream urine sample, and the amount of protein excretion was measured in 24-hour urine collected on the subsequent day. The correlation between the spot P/C ratio and 24-hour urine protein excretion was assessed. Diagnostic value of P/C ratio was expressed in terms of specificity and sensitivity. The receiver operating characteristic curve analysis was used to determine the best discriminator values of the spot urine P/C ratios for preeclampsia [proteinuria >/= 300 mg/24 h]. There was a strong correlation between the spot P/C ratio and 24-hour urine protein excretion [r = 0.84; P < .001]. The optimal spot P/C ratio cutoff point was 0.20 for 300 mg/24 h of protein excretion [preeclampsia], with a sensitivity, specificity, positive predictive value, and negative predictive value of 91.2%, 87.8%, 94.4%, and 96.8%, respectively. The spot P/C ratios less than 0.19 yielded a sensitivity of 100% for exclusion of preeclampsia. We found that there is a significant correlation between the spot urine P/C ratio and 24-hour urine protein excretion in women with preeclampsia. Urine P/C ratio could be used for exclusion of preeclampsia

Isolation and identification of anionic surfactant degrading bacteria from activated sludge

Linear alkylbenzene sulfonate [LABS] is an anionic surfactant widely used all over the world. They will eventually end-up and accumulate in household or industrial sewage. Due to their high foaming capabilities which can cause numerous problems in sewage treatment facilities as well as direct toxic effects on many different organisms in ecosystem; they are generally considered as serious pollutants. Many reports have indicated that common bacteria can readily degrade LABS. In this survey, two different bacteria were isolated from Tehran municipal active sludge that showed the ability to degrade LABS rapidly and actively upon using it as their sole source of carbon. Biochemical tests as well as 16S rRNA gene sequencing performed. Results have indicated the two isolates to be Acinetobacter johnsoni and Pseudomonas beteli. After experiments to optimize the pH and temperature for growth of the two bacterial isolates, the extent of LABS, utilization was evaluated by HPLC method. The Pseudomonas beteli and Acinetobacter johnsoni isolates were able to degrade 96.4% and 97.2% of the original LABS levels after 10 days of growth, respectively. Mixed culture of the two isolates did not significantly increase LABS utilization [97.6%]. Our study showed the ability of two isolated steains to rapidly biodegrade LABS under aerobic conditions